Company & Sponsor Intelligence
Boehringer Ingelheim
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials12
Recruiting0
Completed11
Countries2
Therapeutic footprint
alzheimersdepressionother_neurologyparkinsonsschizophrenia
Indexed studies
NCT04602221A Study in Healthy Men to Test Whether BI 409306, BI 425809 or Lamotrigine Can Reverse the Memory Problems Caused by Ketamine
other_neurology · United StatesPHASE1
other_neurology · United StatesPHASE1
NCT04937829A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication
depression · United StatesPHASE1
depression · United StatesPHASE1
NCT02248220Efficacy and Tolerability of Sifrol® (Pramipexole) in Patients With Advanced Idiopathic Parkinson's Disease
parkinsons · COMPLETED
parkinsons · COMPLETED
NCT06791122A Prospective Cohort Study to Assess Clinical Effectiveness of an Investigational Digital Therapeutic (CT-155) in Patients With Experiential Negative Symptoms of Schizophrenia
schizophrenia · United StatesNA
schizophrenia · United StatesNA
NCT05211947A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study
schizophrenia · United StatesPHASE3
schizophrenia · United StatesPHASE3
NCT00297778Pramipexole Versus Placebo in Parkinson's Disease (PD) Patients With Depressive Symptoms
parkinsons · AustriaPHASE4
parkinsons · AustriaPHASE4
NCT00466167Pivotal Study in Advanced Parkinsons Disease Patients
parkinsons · AustriaPHASE3
parkinsons · AustriaPHASE3
NCT04860830CONNEX-3: A Study to Test Whether Iclepertin Improves Learning and Memory in People With Schizophrenia
schizophrenia · United StatesPHASE3
schizophrenia · United StatesPHASE3
NCT02231255Post Marketing Surveillance Study in Patients With Idiopathic Parkinson's Disease
parkinsons · COMPLETED
parkinsons · COMPLETED
NCT00274131Long-term Administration Study of SND 919 Tablets in Parkinson's Disease
parkinsons · PHASE3
parkinsons · PHASE3
NCT00601523Long-term Safety Study of Open-label Pramipexole Extended Release (ER) in Patients With Early Parkinson´s Disease (PD).
parkinsons · United StatesPHASE3
parkinsons · United StatesPHASE3
NCT02788513BI 425809 in Patients With Cognitive Impairment Due to Alzheimer's Disease.
alzheimers · United StatesPHASE2
alzheimers · United StatesPHASE2
Intelligence layer updated: 2026-10-11 23:31:09.606883+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →